On the basis of the present data, the potential of FLT3LG to augment the effectiveness of anti-PD-1 therapy may be attributed to the promotion of immune cell proliferation and infiltration in TME (tumor microenvironment), with a particular emphasis on T cells. Here, FLT3LG is linked to neoplasm.